About this document "2025 12 xx History PSA MRD T.jpg": What is my MRD and mets as of latest readings

January 29, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

I can see this document contains a graphical tracking of PSA (Prostate-Specific Antigen) measurements over time, which is commonly used to monitor prostate cancer treatment response and detect potential recurrence.

What These Terms Generally Mean:

PSA (Prostate-Specific Antigen): A protein produced by both normal and cancerous prostate cells. Doctors use PSA blood tests to monitor disease activity. Rising PSA levels after treatment may indicate cancer recurrence, while stable or declining levels generally suggest good treatment response.

MRD (Minimal Residual Disease): In prostate cancer, this refers to very small amounts of cancer that may remain after treatment but aren't detectable by standard imaging. Ultra-sensitive PSA tests can sometimes detect MRD before it becomes visible on scans.

Mets (Metastases): Cancer that has spread from the prostate to other parts of the body, most commonly bones or lymph nodes.

🚨 Important - I Cannot Interpret Your Results

I cannot determine your MRD status or metastatic disease status from this document because:

  • Interpreting individual PSA trends requires your complete clinical context
  • MRD and metastatic status require correlation with imaging studies, physical exam, and other clinical factors
  • Your doctor needs to evaluate PSA values alongside your treatment history, symptoms, and other test results
  • The document notes some data ranges as "lost," which affects interpretation

Critical Questions to Ask Your Doctor:

  1. About PSA trends: "What does my current PSA level indicate about my disease status? How does this compare to my previous readings?"

  2. About MRD: "Based on my PSA levels and imaging, do I have evidence of minimal residual disease? What does this mean for my treatment plan?"

  3. About metastases: "Do my current tests show any evidence of metastatic disease? What imaging or additional tests would help clarify this?"

  4. About monitoring: "How often should we monitor my PSA? What PSA level or trend would trigger a change in my treatment approach?"

  5. About next steps: "Given my current PSA pattern, what are the recommended next steps according to current NCCN Guidelines for prostate cancer monitoring?"

According to NCCN Guidelines for Prostate Cancer, PSA monitoring schedules and interpretation depend on your specific treatment history, initial disease stage, and risk category—factors only your oncologist can evaluate with your complete [ID removed]

This information is for educational purposes only. I cannot interpret your individual results. Please discuss these specific findings with your healthcare team for personalized medical guidance and to understand your current MRD and metastatic status.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...

TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2